Xeris Biopharma Holdings (XERS) EBITDA Margin Growth (3y) (2023 - 2026)
Xeris Biopharma Holdings (XERS) EBITDA Margin Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 4,766.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,766.00 |
| Mar 31, 2026 | 4,952.00 |
| Dec 31, 2025 | 6,532.00 |
| Sep 30, 2025 | 7,223.00 |
| Jun 30, 2025 | 8,101.00 |
| Mar 31, 2025 | 12,658.00 |
| Dec 31, 2024 | 22,805.00 |
| Sep 30, 2024 | 19,648.00 |
| Jun 30, 2024 | 27,251.00 |
| Mar 31, 2024 | 16,922.00 |
| Dec 31, 2023 | 25,200.00 |
| Sep 30, 2023 | 13,605.00 |